Inovio Pharmaceuticals
Open
$1.11
Prev. Close
$1.11
High
$1.11
Low
$1.11
Market Snapshot
$76M
-0.9
-3.99
$217.76K
112
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Recently from Cashu
Inovio Advances VGX-3100 for Cervical Dysplasia with Successful Phase 3 Trial Results
Inovio Pharmaceuticals is achieving significant advancements through its partnership with ApolloBio in the development of VGX-3100, an investigational DNA immunotherapy aimed at treating cervical dysp…
Inovio Pharmaceuticals Advances INO-3107 Approval for Recurrent Respiratory Papillomatosis Treatment
Inovio Pharmaceuticals (Ticker: INO) focuses on the advancement of its lead candidate, INO-3107, which is currently undergoing a crucial review process by the U.S. FDA. With a Prescription Drug User F…
Inovio Pharmaceuticals Showcases Innovative DNA Therapies at Major Scientific Conferences
Inovio Pharmaceuticals actively engages in scientific discourse and innovation through its upcoming presentations at two prestigious conferences, underlining its commitment to advancing DNA medicine.…
Inovio Pharmaceuticals Faces Major Legal Challenges Amid Promising Biotech Innovations
Legal Challenges Loom Over Inovio Pharmaceuticals' Future Inovio Pharmaceuticals, Inc., a prominent player in the biotechnology sector focusing on DNA medicines for HPV-related diseases, cancer, and i…